# Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05652868/  
OnCo record `nct05652868` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of MYTX-011 run by Mythic Therapeutics, terminated.

## Summary

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT05652868 by Mythic Therapeutics, with 227 participants enrolled, started 2023-03-23. Conditions recorded: NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer and Advanced Non-Small Cell Non-Squamous Lung Cancer. Interventions recorded: MYTX-011.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05652868
- Phase: 1
- Setting: A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01
- Sponsor: Mythic Therapeutics
- Enrolled: 227

## Sources

- ClinicalTrials.gov NCT05652868: https://clinicaltrials.gov/study/NCT05652868

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [MYTX-011](https://onco.cc/drugs/mytx-011/)
- companies: [Mythic Therapeutics](https://onco.cc/companies/mythic-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05652868.json